Terbutaline Sulfate Injection, USP is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
From the U.S. FDA-approved label for Terbutaline. Full label: DailyMed.
Terbutaline Sulfate Injection, USP is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
From the U.S. FDA-approved label for Terbutaline. Full label: DailyMed.
Vials should be used only for subcutaneous administration and not intravenous infusion. Sterility and accurate dosing cannot be assured if the vials are not used in accordance with DOSAGE AND ADMINISTRATION. Discard unused portion after single patient use.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Prolonged Tocolysis Terbutaline sulfate has not been approved and should not be used for prolonged tocolysis (beyond 48-72 hours). In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting (see BOXED WARNING: Prolonged Tocolysis ). Hypersensitivity Terbutaline sulfate injection is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Deterioration of Asthma Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of terbutaline sulfate than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti‑inflammatory treatment, e.g., corticosteroids. Use of Anti-Inflammatory Agents The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
Adverse reactions observed with terbutaline sulfate injection are similar to those commonly seen with other sympathomimetic agents. All these reactions are transient in nature and usually do not require treatment.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
10 products from 6 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Aerodyn-T Syrup | Terbutaline (1.5mg) | Century Life Science | bottle of 60 ml Syrup |
| Astharid T Tablet | Terbutaline (NA) | Empiai Pharmaceuticals Pvt Ltd | strip of 10 tablets |
| Bricanyl 0.5mg Injection | Terbutaline (0.5mg) | AstraZeneca | vial of 1 ml Injection |
| Bricanyl 250mcg Inhaler | Terbutaline (250mcg) | AstraZeneca | bottle of 200 MDI Inhaler |
| Bricanyl 5mg Tablet | Terbutaline (5mg) | AstraZeneca | packet of 20 tablets |
| Bricawin 1.5mg Syrup | Terbutaline (1.5mg) | Ikon Remedies Pvt Ltd | bottle of 100 ml Syrup |
| Terbujel 1.5mg Syrup | Terbutaline (1.5mg) | Astrum Healthcare Pvt Ltd | bottle of 100 ml Syrup |
| Terbutaline Sulpha 0.5mg Injection | Terbutaline (0.5mg) | AstraZeneca | vial of 1 ml Injection |
| Tetrasma 2.5mg Tablet | Terbutaline (2.5mg) | Medopharm | strip of 10 tablets |
| Tetrasma 5mg Syrup | Terbutaline (5mg) | Medopharm | bottle of 60 ml Syrup |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store at 20° to 25°C (68° to 77°F). Protect from light by storing vials in original carton until dispensed.
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
